Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Conduit Pharmaceuticals ( (CDT) ) is now available.
On December 28 and 29, 2025, CDT Equity Inc. entered into consulting agreements with Thesprogen, PC and NJS Foresight Bio-Advisory, LLC to strengthen both its pre-clinical development and its commercial out-licensing strategy. Thesprogen will analyze CDT’s recent pre-clinical data on AZD1656 and advise on optimizing development, including potential human organ models in COPD and fibrosis indications, as well as help refine the company’s press releases and public messaging over a six‑month term, for which CDT compensated the firm with 108,392 common shares valued at $155,000. NJS Foresight Bio-Advisory will provide 12 months of advisory and business development services to identify and support potential licensing partners for CDT’s solid-form asset portfolio, receiving a $150,000 retainer and success-based commissions of 8% of the announced value of any out-licensing transactions, with both retainer and commissions payable in cash or stock; on December 29, 2025, CDT issued 104,896 common shares in lieu of the cash retainer. The January 2, 2026 announcement of the NJS engagement underscores CDT’s push to monetize its solid-form patent portfolio—targeting drugs approaching patent cliffs and offering partners extended protection and lifecycle management options—and reflects a broader strategy to unlock value through licensing and royalty-based deals that could enhance its commercial reach and appeal to stakeholders seeking returns from its intellectual property and deal-making capabilities.
More about Conduit Pharmaceuticals
CDT Equity Inc. (formerly Conduit Pharmaceuticals) is a data‑driven biopharmaceutical development company that focuses on identifying, enhancing and advancing therapeutic assets through scientific innovation and strategic partnerships. The Nasdaq-listed firm leverages artificial intelligence, solid-form chemistry and asset repositioning to develop novel treatments, has built a portfolio of solid-form patents such as cocrystals and salts that can improve solubility, bioavailability and delivery modes while extending patent protection, and also pursues a cryptocurrency treasury reserve strategy centered initially on Bitcoin to diversify capital allocation and support its financial position.
Average Trading Volume: 379,426
Technical Sentiment Signal: Sell
Current Market Cap: $2.09M
Learn more about CDT stock on TipRanks’ Stock Analysis page.